Divi's Laboratories Limited (IN:DIVISLAB)
:DIVISLAB
DIVISLAB Stock Chart & Stats
₹6603.05
-₹20.75(-0.35%)
At close: 4:00 PM EST
₹6603.05
-₹20.75(-0.35%)
Day’s Range― - ―
52-Week Range₹4,941.70 - ₹7,077.70
Previous CloseN/A
Volume63.15K
Average Volume (3M)6.36K
Market Cap
₹1.60T
Enterprise Value₹1.56T
Total Cash (Recent Filing)₹32.61B
Total Debt (Recent Filing)₹900.00M
Price to Earnings (P/E)72.7
Beta0.86
Next Earnings
May 25, 2026EPS Estimate
25.33Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)21.98
Shares Outstanding265,468,570
10 Day Avg. Volume6,055
30 Day Avg. Volume6,356
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)9.84
Price to Sales (P/S)15.74
P/FCF Ratio290.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)97.57
Revenue Forecast (FY)₹106.19B
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthVery low leverage and a high equity ratio provide durable financial flexibility. This reduces refinancing risk, supports capex and capacity expansion for large-scale manufacturing, and preserves ability to sustain multi-year supply contracts and withstand demand cycles without stressing liquidity.
Profitability / Margin StrengthSustained high net and operating margins indicate structural efficiency and pricing power in APIs and custom synthesis. Strong margins foster internal cash generation, fund R&D or capex, and provide a buffer against raw material inflation, supporting long-term competitive positioning.
Business Model & Competitive PositionA dual revenue model of large-scale generic API supply plus higher-value custom synthesis creates diversification and sticky customer relationships. Process chemistry expertise and scale are durable competitive advantages for winning long-term CRAMS engagements and maintaining cost competitiveness.
Bears Say
Free Cash Flow VolatilityExtreme swings in free cash flow growth signal inconsistent cash conversion driven by timing of project receipts or working capital swings. Persistent volatility complicates capital allocation, dividend consistency and funding for capacity expansion despite reported strong operating cash flow coverage.
Gross Margin Compression RiskA material decline in gross margin implies structural mix shifts or rising input/competitive pressures. If sustained, lower gross margins reduce the cushion for operating expenses and may erode long-term profitability and returns, forcing the company to rely more on volume or cost cuts.
Moderate Recent Revenue Growth / Demand CyclicalityModest latest-period top-line growth combined with dependence on project ramps and customer lifecycles makes revenue lumpy. This limits visibility for steady multi-year expansion and raises execution risk versus peers, especially if new contract wins or scale-ups slow amid competitive pressures.
Divi's Laboratories Limited News
DIVISLAB FAQ
What was Divi's Laboratories Limited’s price range in the past 12 months?
Divi's Laboratories Limited lowest stock price was ₹4941.70 and its highest was ₹7077.70 in the past 12 months.
What is Divi's Laboratories Limited’s market cap?
Divi's Laboratories Limited’s market cap is ₹1.60T.
When is Divi's Laboratories Limited’s upcoming earnings report date?
Divi's Laboratories Limited’s upcoming earnings report date is May 25, 2026 which is in 60 days.
How were Divi's Laboratories Limited’s earnings last quarter?
Divi's Laboratories Limited released its earnings results on Feb 11, 2026. The company reported ₹21.98 earnings per share for the quarter, missing the consensus estimate of ₹23.173 by -₹1.193.
Is Divi's Laboratories Limited overvalued?
According to Wall Street analysts Divi's Laboratories Limited’s price is currently Overvalued.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.46%. See more information on Divi's Laboratories Limited dividends here
What is Divi's Laboratories Limited’s EPS estimate?
Divi's Laboratories Limited’s EPS estimate is 25.33.
How many shares outstanding does Divi's Laboratories Limited have?
Divi's Laboratories Limited has 265,468,570 shares outstanding.
What happened to Divi's Laboratories Limited’s price movement after its last earnings report?
Divi's Laboratories Limited reported an EPS of ₹21.98 in its last earnings report, missing expectations of ₹23.173. Following the earnings report the stock price went up 4.889%.
Which hedge fund is a major shareholder of Divi's Laboratories Limited?
Currently, no hedge funds are holding shares in IN:DIVISLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Divi's Laboratories Limited
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Lupin Limited
―
Suven Life Sciences Limited
―
Torrent Pharmaceuticals Ltd
―